Senicapoc Struktur

Senicapoc

Bezeichnung:Senicapoc

CAS-Nr289656-45-7

Englisch Name:Senicapoc

CBNumberCB31261049

SummenformelC20H15F2NO

Molgewicht323.34

MOL-Datei289656-45-7.mol

Senicapoc physikalisch-chemischer Eigenschaften

Schmelzpunkt	180-181 °C(Solv: hexane (110-54-3); dichloromethane (75-09-2))
Siedepunkt	460.7±45.0 °C(Predicted)
Dichte	1.250±0.06 g/cm3(Predicted)
storage temp.	Sealed in dry,Store in freezer, under -20°C
Löslichkeit	DMSO : 50 mg/mL (154.64 mM; Need ultrasonic)
Aggregatzustand	Powder
pka	15.41±0.50(Predicted)
Farbe	White to yellow
InChI	InChI=1S/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24)
InChIKey	SCTZUZTYRMOMKT-UHFFFAOYSA-N
SMILES	C(C1C=CC=CC=1)(C1C=CC(F)=CC=1)(C1C=CC(F)=CC=1)C(=O)N

Senicapoc Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Senicapoc is an inhibitor of intermediate conductance calcium-activated potassium (IK_Ca1/K_Ca3.1) channels. It inhibits rubidium efflux from and dehydration of isolated human red blood cells (RBCs) induced by the calcium ionophore A23187 (; IC₅₀s = 11 and 30 nM, respectively). Senicapoc (10 mg/kg twice per day) reduces IK_Ca1/K_Ca3.1 channel activity, increases potassium levels in RBCs, and decreases erythrocyte density in the SAD transgenic mouse model of sickle cell disease. It inhibits IL-2, IFN-γ, IL-12, and IL-17A production in CD3⁺ T cells stimulated with phorbol 12-myristate 13-acetate (PMA; ) and ionomycin (Item Nos. 10004974 | 11932) when used at a concentration of 1 μM. Senicapoc (100 mg/kg) increases the paw withdrawal threshold in a rat model of chronic constriction injury (CCI) of the sciatic nerve.
Verwenden
Treatment of disorders mediated by a calcium activated intermediate conductance potassium ion channel antagonist.
Definition
Senicapoc (ICA-17043; bis(4-fluorophenyl)phenyl acetamide), a selective, highly potent Gardos channel blocker (IC50 = 11 nM), specifically inhibits the efflux of potassium from the RBCs of both SCD transgenic mice and human sickle cell disease patients. It is derived from clotrimazole-1, a KCNN4 inhibitor. Senicapoc is well tolerated by both healthy volunteers and patients with SCD and has favourable pharmacokinetics, with a long half-life permitting once-daily dosing. It was designed for long-term sickle cell disease therapy to avoid clotrimazole-1 side effects. Whereas Senicapoc is a potent inhibitor of WT KCNN4, its efficiency on mutated channels was unknown[1-2].
Einzelnachweise
[1] Raphael Rapetti-Mauss. “Senicapoc: a potent candidate for the treatment of a subset of hereditary xerocytosis caused by mutations in the Gardos channel.” Haematologica 101 11 (2016): e431–e435.
[2] Kenneth I Ataga. “Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.” Blood (2008): 3991–7.

Senicapoc Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

289656-45-7, Senicapoc Verwandte Suche:

Send Inquriy